Movement Alert｜ImmunityBio, Inc. Rises 10.13% in Regular Trading, Trading at $10.2101

Market Focus

Yesterday

On October 2, ImmunityBio, Inc. rose 10.13% in regular trading, trading at $10.2101 USD/share, with Turnover of $41.80 million.

Within the Biotechnology sector where ImmunityBio, Inc. belongs, the overall sector performance was weak. Among individual stocks, Moderna down 0.62%, Amgen down 0.65%, AbbVie down 0.18%, Gilead Sciences down 0.98%, Natera up 0.34%.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines that harness and amplify the immune system to defeat cancers and infectious diseases. The company offers immunotherapy and cell therapy platforms including antibody cytokine fusion protein N-803, vaccine technologies, natural killer cells, and related modalities. Its therapeutic pipeline includes Phase II and III clinical trials targeting bladder, pancreatic, and lung cancers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1181648186"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1181648186\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1181648186?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-10-02 21:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1181648186","market":"us","top_or_hot":-1,"title":"Movement Alert｜ImmunityBio, Inc. Rises 10.13% in Regular Trading, Trading at $10.2101","media":"Market Focus","content":"<p><p>On October 2, ImmunityBio, Inc. rose 10.13% in regular trading, trading at $10.2101 USD/share, with Turnover of $41.80 million.</p><p>Within the Biotechnology sector where ImmunityBio, Inc. belongs, the overall sector performance was weak. Among individual stocks, Moderna down 0.62%, Amgen down 0.65%, AbbVie down 0.18%, Gilead Sciences down 0.98%, Natera up 0.34%.</p><p>ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines that harness and amplify the immune system to defeat cancers and infectious diseases. The company offers immunotherapy and cell therapy platforms including antibody cytokine fusion protein N-803, vaccine technologies, natural killer cells, and related modalities. Its therapeutic pipeline includes Phase II and III clinical trials targeting bladder, pancreatic, and lung cancers.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ImmunityBio, Inc. Rises 10.13% in Regular Trading, Trading at $10.2101</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ImmunityBio, Inc. Rises 10.13% in Regular Trading, Trading at $10.2101\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-10-02 21:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On October 2, ImmunityBio, Inc. rose 10.13% in regular trading, trading at $10.2101 USD/share, with Turnover of $41.80 million.</p><p>Within the Biotechnology sector where ImmunityBio, Inc. belongs, the overall sector performance was weak. Among individual stocks, Moderna down 0.62%, Amgen down 0.65%, AbbVie down 0.18%, Gilead Sciences down 0.98%, Natera up 0.34%.</p><p>ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines that harness and amplify the immune system to defeat cancers and infectious diseases. The company offers immunotherapy and cell therapy platforms including antibody cytokine fusion protein N-803, vaccine technologies, natural killer cells, and related modalities. Its therapeutic pipeline includes Phase II and III clinical trials targeting bladder, pancreatic, and lung cancers.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"","article_id":"1181648186","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1181648186","pubTimestamp":1790949339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On October 2, ImmunityBio, Inc. rose 10.13% in regular trading, trading at $10.2101 USD/share, with Turnover of $41.80 million.Within the Biotechnology sector where ImmunityBio, Inc. belongs, the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc."},"translate_title":"走势警报|ImmunityBio, Inc. 常规交易中上涨 10.13%，交易价格为 10.2101 美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":1},"content_text":"On October 2, ImmunityBio, Inc. rose 10.13% in regular trading, trading at $10.2101 USD/share, with Turnover of $41.80 million.Within the Biotechnology sector where ImmunityBio, Inc. belongs, the overall sector performance was weak. Among individual stocks, Moderna down 0.62%, Amgen down 0.65%, AbbVie down 0.18%, Gilead Sciences down 0.98%, Natera up 0.34%.ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines that harness and amplify the immune system to defeat cancers and infectious diseases. The company offers immunotherapy and cell therapy platforms including antibody cytokine fusion protein N-803, vaccine technologies, natural killer cells, and related modalities. Its therapeutic pipeline includes Phase II and III clinical trials targeting bladder, pancreatic, and lung cancers.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}